Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Individual InvestingForge MarketplaceFind new private company investment opportunities​Browse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Forge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Liquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All insights Reports and highlights News and trends Private market education Tips and tutorials Forge Investment OutlookPrivate Market UpdatesIPO calendarPrivate Magnificent 7Emerging trendsPrivate company newsUpcoming IPOsAll guidesPrivate market basicsPrivate shares transactionsValuations, pricing and market trendsSelling in the private marketFAQsGlossaryCompany page and tradesProof of ownershipBid and ask submissionsForge fund offeringsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Who We Serve
Individual Investors
Institutional Investors
What We Do
Trading
Individual Investing
Institutional Trading
Data
Liquidity Programs
Retirement
Self-Directed IRA
Insights
Reports and highlights
News and trends
Private market education
Tips and tutorials
About
Log In
Sign Up
Secondary marketplace / Explore private companies / CytoVale IPO
CytoVale

CytoVale IPO

$333.35MM
Series D Valuation, Oct 2024
Artificial Intelligence
Buy And Sell CytoVale StockLearn More About CytoVale StockAdd To Watchlist
Register for details
For more details on financing and valuation for CytoVale, register or log in.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Log In

CytoVale IPO date and status

2013
Founded
IPO Mentioned
Confidential Filing
S-1 Filed
IPO

Company details

CytoVale is a biotechnology research company that uses early detection strategies for auto-immune diseases. The company has a mission of using diagnostic interventions to create faster, easier-to-implement medical treatment for patients. Other features of CytoVale are microfluidics and biophysical machine learning. CytoVale was founded by Ajay Shah and Dino Di Carlo in 2013 and is headquartered in San Francisco, CA.
www.cytovale.com/
Sector
Healthcare
Subsector
Healthcare Providers & Services
Founded
2013
Headquarters
South San Francisco, CA, United States
Founders
Ajay Shah, Ph.D., Henry Tse, Ph.D.
Forge Price 1
Price not yet available
Market Activity 2
Limited
Last Matched Price
Get Full Access
Post-Money Valuation 3
$333.35MM
Total Funding
$204.3MM
Last Funding Round
Series D

Learn more about CytoVale

To invest in CytoVale pre-IPO

Can you invest in CytoVale pre-IPO?

CytoVale is privately held and not traded on public markets, so pre-IPO investments are available only to accredited investors.

If you’re already accredited and have completed Forge’s verification, you can visit our marketplace to review and invest in private companies ahead of an IPO.

If you haven’t yet completed your accredited investor verification with Forge, you can start that process now to unlock access to new private-company offerings.

For more on who qualifies—and how to get verified—see our blog “Accredited investors, qualified clients and qualified purchasers: Who can invest?”

Can you sell shares of CytoVale before it goes public?

Yes, subject to any contractual or corporate transfer restrictions, it is possible to list your shares to sell while CytoVale is still private. If you’re considering selling, you can register today for free to get started. Once registered, you can evaluate pricing insights and market activity to inform your decision, then post your shares for sale and set the terms, like quantity and price—all directly through our platform.

If you’d like additional guidance at any point, Forge private market specialists are available to help. For a step-by-step overview, check out our seller’s guide.

What is the pre-IPO value of my CytoVale shares?

To explore the value of your CytoVale shares, create a free account to access Forge’s marketplace. Once inside, you’ll find several pricing insights to help guide your decision—these include historical transaction data, a live order book showing current buy and sell interest, and Forge Price™, a derived, indicative price based on recent transactions, investor activity, and other relevant market data.

These insights can help you determine a price you’re comfortable with if you choose to sell your shares. If you’d like additional guidance along the way, Forge private market specialists are available to help. You can also review our seller’s guide for a step-by-step overview.

Is CytoVale a publicly traded company?

CytoVale is a private company and not publicly traded.

If you’re interested in buying or selling shares in private companies, you can register with Forge today for free to explore available opportunities. Once registered, you’ll gain access to our marketplace, where you can view active buy and sell interest, evaluate pricing signals and take action directly through the platform.

To learn more about CytoVale potential IPO

Will CytoVale go IPO?

CytoVale has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2025.

What is CytoVale’s IPO price?

The CytoVale IPO price does not exist at this time, as CytoVale is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to CytoVale, register for Forge today.

When was CytoVale founded?

CytoVale was founded in 2013.

What is CytoVale funding to date?

CytoVale has raised $204.3MM to date.

CytoVale major investors

Alumni Ventures
Baidu Ventures
Biomedical Advanced Research & Development Authority
Blackhorn Ventures
Breakout Labs
Breakout Ventures
Cpp Investments
Dolby Family Ventures
Farmore Capital Group
Freerun Ventures
Global Health Investment Fund
Google For Startups Accelerator
Grids Capital
Kayyak Ventures
National Institutes Of Health
National Science Foundation
Netscientific
Norwest Venture Partners
Pactolus Ventures
Pathway Bioventures
Sands Capital
U.S. Department Of Health & Human Services
Western Technology Investment
Show All InvestorsShow Fewer Investors

CytoVale pre-IPO valuation and funding rounds

Funding history chart
Funding round and deals details
Funding Date Round Amount Raised Price per Share Post-Money Valuation 3 Key Investors
10/10/2024 Series D $101MM $2.77 $333.35MM Alumni Ventures, Breakout Ventures, Cpp Investments, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital
Price per Share
$ xx.xx
Shares Outstanding
36,422,641
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alumni Ventures, Breakout Ventures, Cpp Investments, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital
11/15/2023 Series C-1 $54.87MM $2.29 $188.41MM Alumni Ventures, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital
Price per Share
$ xx.xx
Shares Outstanding
23,940,484
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alumni Ventures, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital
11/15/2023 Series C-2 $18.7MM $1.95 $188.41MM Alumni Ventures, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital
Price per Share
$ xx.xx
Shares Outstanding
9,600,482
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alumni Ventures, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital
11/15/2023 Series C-4 $178,987.00 $1.72 $188.41MM Alumni Ventures, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital
Price per Share
$ xx.xx
Shares Outstanding
104,117
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alumni Ventures, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital
11/15/2023 Series C-3 $10.24MM $1.49 $188.41MM Alumni Ventures, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital
Price per Share
$ xx.xx
Shares Outstanding
6,874,563
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alumni Ventures, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital
10/30/2019 Series B $15MM $2.67 $47.02MM Blackhorn Ventures, Breakout Ventures, Western Technology Investment
Price per Share
$ xx.xx
Shares Outstanding
5,614,823
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Blackhorn Ventures, Breakout Ventures, Western Technology Investment
06/10/2014 Series A $4.3MM $1.35 $10.75MM Dolby Family Ventures
Price per Share
$ xx.xx
Shares Outstanding
3,185,185
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Dolby Family Ventures

CytoVale IPO news and media highlights

PR Newswire 10/10/2024

Cytovale Completes $100 Million Series D Funding to Accelerate Commercial Expansion of its Rapid Sepsis Solution

Cytovale®, a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, today announced it has raised $100 million in Series D funding led by Sands Capital. The round included participation from new investor Canada Pension Plan Investment Board (CPP Investments), as well as existing investors Norwest Venture Partners, Global Health Investment Corporation and Breakout Ventures, an early backer of the company. Cytovale will use the funding to build upon its early clinical success and accelerate commercial expansion of IntelliSep to more hospital emergency departments (ED) and health systems nationwide.
FierceBiotech 11/16/2023

Cytovale collects $84M to roll out its rapid ER sepsis diagnostic test

After recently launching its emergency room-focused diagnostic for catching early cases of sepsis, Cytovale has raised $84 million in venture capital funding to bolster the system’s rollout. According to the San Francisco-based company, sepsis contributes to more than one-third of all in-hospital deaths—more than 350,000 annually in the U.S.—with about 80% of patients with the bloodstream condition spending at least some time in the ER.
Medical Device Network 01/19/2023

Cytovale’s test gets FDA 510(k) clearance for early sepsis detection

Medical diagnostics company Cytovale has secured 510(k) clearance from the US Food and Drug Administration (FDA) for IntelliSep, its test for the early detection of sepsis. IntelliSep has been designed to help clinicians recognise sepsis and make time-sensitive critical decisions. It provides test results within ten minutes. It is claimed to be the first FDA-approved diagnostic tool for evaluating cellular host response to help identify patients with sepsis in emergency departments.
Browse More Insights

Private companies exploring an IPO

See which private companies are preparing for the public market. Register to get full access to the latest secondary market pricing data.

Sector: Healthcare
Subsector: Healthcare Providers & Services
Trade Metrics Last Funding Round
Company Forge Price Last Matched Round Post-Money Valuation 3 Price Per Share Amount Raised
Generate BiomedicinesGenerate BiomedicinesNot available$ xx.xxSeries C$1.95B$11.85$288MM
Spyglass PharmaSpyglass PharmaNot available$ xx.xxSeries D$350.04MM$2.33$75MM
Affinia TherapeuticsAffinia TherapeuticsNot available$ xx.xxSeries C$156.61MM$1.62$40MM
OriginOriginNot available$ xx.xxNot available------
See Tech IPO Calendar

Private market movers

Track trading activity and investor momentum across thousands of private companies. Register to view last matched prices and additional transactional details.

Actively traded

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
SpaceX SpaceX $550.00 +$102.77 (22.98%)High $xxx.xx
Anduril Anduril $114.78 +$9.78 (9.31%)High $xxx.xx
Databricks Databricks $197.72 +$0.06 (0.03%)High $xxx.xx
See All Actively Traded Companies

Artificial Intelligence (AI)

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
Anduril Anduril $114.78 +$9.78 (9.31%)High $xxx.xx
Databricks Databricks $197.72 +$0.06 (0.03%)High $xxx.xx
Figure AI Figure AI $174.00 -$20.00 (10.31%)Limited $xxx.xx
See All AI Companies

Forge, your trusted partner for pre-IPO insights and CytoVale data

Forge is the trusted platform for buying and selling pre-IPO shares. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

Register

Updated on: Jul 16, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions on Forge.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. Actively traded companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.